Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Birhiray, R. E.
21  Ergebnisse:
Personensuche X
?
1

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMI..:

Rifkin, R. M. ; Costello, C. L. ; Birhiray, R. E....
HemaSphere.  6 (2022)  - p. 837-838 , 2022
Link: https://doi.org/10.1097/..
 
?
2

Atypical identification of Lynch syndrome by immunohistoche..:

McIlvried, D. E. ; Birhiray, R. E. ; Lu, J. Z.
Familial Cancer.  9 (2010)  3 - p. 377-381 , 2010
Link: https://doi.org/10.1007/..
 
?
3

P947: Comparative Effectiveness of Oral Ixazomib-Lenalidomi..:

Rifkin, R.M ; Costello, C.L ; Birhiray, R.E...
10.1097/01.HS9.0000846656.55700.df.  , 2022
Link: https://hdl.handle.net/1..
 
?
4

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMI..:

Rifkin, R. M ; Costello, C. L ; Birhiray, R. E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431289/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
5

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMI..:

R. M. Rifkin ; C. L. Costello ; R. E. Birhiray...
http://journals.lww.com/10.1097/01.HS9.0000846656.55700.df.  , 2022
Link: https://doi.org/10.1097/..
 
?
6

Humanized monoclonal Campath-H1 can mimic allo antibodies i..:

Wagenknecht, Dawn R. ; Sizemore, Jill M. ; House, Kimberley D...
Human Immunology.  65 (2004)  9-10 - p. S73 , 2004
Link: https://doi.org/10.1016/..
 
?
7

A Feasibility Trial of Concurrent Radiation, Temozolomide, ..:

Liebross, R.H. ; Birhiray, R. ; Schultz, S....
International Journal of Radiation Oncology*Biology*Physics.  81 (2011)  2 - p. S275 , 2011
Link: https://doi.org/10.1016/..
 
?
8

A Feasibility Trial of Concurrent Radiation, Temozolomide, ..:

Liebross, R.H. ; Leagre, C. ; Schultz, S....
International Journal of Radiation Oncology*Biology*Physics.  75 (2009)  3 - p. S125 , 2009
Link: https://doi.org/10.1016/..
 
?
9

Practical strategies for creating diversity, equity, inclus..:

Birhiray, Maya N. ; Birhiray, Ruemu E.
Blood Advances.  7 (2023)  8 - p. 1507-1512 , 2023
Link: https://doi.org/10.1182/..
 
?
10

In-Class Transition from Bortezomib-Based Therapy to IRd is..:

Rifkin, Robert M ; Costello, Caitlin L ; Birhiray, Ruemu E...
Future Oncology.  20 (2023)  3 - p. 131-143 , 2023
Link: https://doi.org/10.2217/..
 
?
11

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO O..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger M....
HemaSphere.  7 (2023)  S3 - p. e149880d , 2023
Link: https://doi.org/10.1097/..
 
?
12

In-class transition (iCT) of proteasome inhibitor-based the..:

Rifkin, Robert M. ; Girnius, Saulius K. ; Noga, Stephen J....
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
13

POSTER: MM-465 In-Class Transition (iCT) from Parenteral Bo..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S221 , 2023
Link: https://doi.org/10.1016/..
 
?
14

MM-465 In-Class Transition (iCT) from Parenteral Bortezomib..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S501 , 2023
Link: https://doi.org/10.1016/..
 
?
15

MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patie..:

Manda, Sudhir ; Yimer, Habte A. ; Birhiray, Ruemu E....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S416-S417 , 2022
Link: https://doi.org/10.1016/..
 
1-15